The FDA has approved a new drug for the treatment of early-stage Alzheimer’s disease even though clinical trial results showed modest cognitive benefits.
describes a patient with Alzheimer’s who died after taking lecanemab.Still, in anticipation of accelerated approval of lecanemab and the anti-amyloid drug donanemab, which the FDA has also fast-tracked, the Alzheimer's Association filed a formal request last month with the Centers for Medicare & Medicaid Services to provide full and unrestricted coverage for FDA-approved Alzheimer’s treatments.
"The current CMS policy to severely limit access to these treatments eliminates people's options, is resulting in continued irreversible disease progression, and contributes to greater health inequities. That's not acceptable," Pike added.welcomes and celebrates this action by the FDA. We now have a second approved treatment that changes the course of Alzheimer’s disease in a meaningful way for people in the early stages of the disease.
"The progress we’ve seen in not only this class of treatments, but also in the diversification of treatment types and targets over the past few years, is exciting and provides real hope to those impacted by this devastating disease," Carrillo said.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA Approves Alzheimer's Drug That Slowed Cognitive Decline in Clinical TrialThe FDA’s decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer’s.
Les mer »
FDA approves new Alzheimer’s drug that appears to slow progression of diseaseBREAKING: FDA approves Alzheimer’s drug shown in clinical trials to slow cognitive decline in patients in the early stages of the illness.
Les mer »
FDA Approves Alzheimer's Drug That Modestly Slows DiseaseThe drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s.
Les mer »
FDA approves Leqembi, Alzheimer's drug that modestly slows diseaseALZHEIMER'S DRUG: The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology. MORE:
Les mer »
FDA approves new experimental Alzheimer's drugThe Food and Drug Administration granted accelerated approval for Eisai and Biogen's experimental Alzheimer's drug, lecanemab, on Friday, offering a new treatment option for the more than 6.5 million people with Alzheimer's in the United States.
Les mer »
FDA approves new Alzheimer's drug lecanemab that appears to slow the memory-robbing diseaseFederal drug regulators on Friday approved lecanemab, sold under the brand name Leqembi, an Alzheimer’s drug that appears to slow the disease.
Les mer »